ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IPSC vs FATE // EV/EBITDA & P/E VALUATION

Century Therapeutics Inc. (NASDAQ) VS. Fate Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: IPSC 5 — FATE 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IPSC VS. FATE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IPSC FATE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -14.10% -35.00% +20.90 IPSC /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -15.80% -60.00% +44.20 IPSC /operating-margins <GO>
Net Profit Margin -8.80% -60.00% +51.20 IPSC /net-margins <GO>
Revenue Growth (YoY) 180.00% -51.20% +231.20 IPSC /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 44.7 45.2 -0.49 FATE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $264.4M $260.0M $4.4M IPSC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IPSC REV FATE REV IPSC GROSS % FATE GROSS % IPSC FCF FATE FCF
FY 2025 $109.2M $6.6M — — -$104.7M -$112.0M
FY 2024 $6.6M $13.6M — — -$110.3M -$123.6M
FY 2023 $2.2M $63.5M — — -$88.3M -$132.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IPSC // BETA —
FATE // BETA —